Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.
Epstein-Barr virus (EBV)-associated postallogeneic stem cell transplantation (SCT) lymphoproliferative disorder (PTLD) is often life threatening. The risk of EBV reactivation is highest in older patients, T cell-depleted SCT (in vivo or vitro), and in unrelated or mismatched SCT. Cumulative numbers of patients with EBV reactivation and PTLD are rising as more patients at high risk for EBV reactivation and PTLD are receiving allo-SCT. Novel but easily applicable strategies are needed to prevent EBV reactivation and PTLD to serve the needs of the increasingly enlarging population of high-risk SCT recipients across the globe.
Reddy
Nishitha
N
Hematology and Stem Cell Transplantation Section, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232-5505, USA.
Rezvani
Katayoun
K
Barrett
A John
AJ
Savani
Bipin N
BN
D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D004279:DNA, Viral / Q000097:blood; D020031:Epstein-Barr Virus Infections / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control* / Q000821:virology; D004854:Herpesvirus 4, Human / Q000502:physiology; D006801:Humans; D016867:Immunocompromised Host; D007165:Immunosuppression Therapy; D008232:Lymphoproliferative Disorders / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control* / Q000821:virology; D012306:Risk; D000069283:Rituximab; D020123:Sirolimus / Q000008:administration & dosage; D033581:Stem Cell Transplantation / Q000009:adverse effects; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000821:virology; D014184:Transplantation, Homologous; D019562:Viral Load; D014775:Virus Activation
D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D004279:DNA, Viral; D000069283:Rituximab; D020123:Sirolimus